With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Are “sin taxes” regressive? This is a common criticism of proposals to increase taxes on “bads” such as tobacco, alcohol, and sugar. There are a number of reasons not to be too concerned by the answer to this question. But still, we were curious, so we took a look at the data.
The Financial Times recently published an opinion calling for more affordable cancer drugs for the world’s poor. Given the growing burden of cancer in developing countries, including across sub-Saharan Africa, it is right to pay more attention to the affordability of cancer treatments in lower- and middle-income countries (LMICs).
In Africa, where widowhood and divorce are common and the rights of women are mostly conditional on marriage, changes in marital status are likely to influence the success of policies aimed at empowering women.
This week the world’s largest conference on issues affecting women and girls, Women Deliver, is being held in Vancouver, Canada. High on the agenda is sexual and reproductive health and rights (SRHR) for women and girls in humanitarian settings.
In March, our team at the Center for Global Development and Office of Health Economics posted a consultation draft of a policy proposal for a Market-Driven, Value-Based Advanced Commitment (MVAC). The MVAC is a new mechanism that puts middle-income country governments in the driver’s seat to accelerate R&D for diseases that affect the world’s poor—specifically, the 10 million men, women, and children who develop tuberculosis (TB) disease each year and desperately need better therapies.
Innovation is a critical tool in the global fight against disease—especially for tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the top 10 causes of death in the world.
In many developing countries health supply chains function poorly, resulting in frequent stockouts and many substandard and even falsified medications—which undermine treatment effectiveness and raise the risk of antimicrobial resistance.